Advertisement
Screener

Beta Bionics, Inc. (BBNX) Graph

BBNX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $32.01M; Cost of revenue $13.11M; Research and development $10.24M; Operating expenses $44.48M.
  • 2026-03-31: Revenue $27.63M; Cost of revenue $11.19M; Research and development $10.36M; Operating expenses $40.71M.
  • 2025-12-31: Revenue $32.12M*; Cost of revenue $13.18M*; Research and development $10.13M*; Operating expenses $35.07M*.
  • 2025-09-30: Revenue $27.25M; Cost of revenue $12.13M; Research and development $8.20M; Operating expenses $32.16M.

Contract With Customer Sales Channel

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

BBNX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Durable MedicalEquipment Channel$20.41MPharmacy BenefitPlan Channel$11.60MRevenue$32.01MCost of revenue$13.11MGross profit$18.90MOperating expenses$44.48MOperating income-$25.58MOther income, net-$2.00KResearch & development$10.24MNet income-$23.40M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30$32.01M$13.11M$10.24M$44.48M-$23.40M
2026-03-31$27.63M$11.19M$10.36M$40.71M-$21.89M
2025-12-31$32.12M*$13.18M*$10.13M*$35.07M*-$13.47M*
2025-09-30$27.25M$12.13M$8.20M$32.16M-$14.21M
2025-06-30$23.24M$10.73M$8.87M$32.38M-$16.87M
2025-03-31$17.64M$8.67M$7.59M$27.61M-$28.66M
2024-09-30$16.70M$7.79M$5.14M$19.89M-$9.74M
2024-06-30$15.05M$6.96M$6.35M$19.87M-$14.46M
2024-03-31$12.93M$5.73M$5.48M$16.65M-$12.45M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30$59.64M$24.30M$20.60M$85.19M-$45.30M
2025-06-30$40.88M$19.40M$16.46M$59.99M-$45.52M
2024-06-30$27.98M$12.69M$11.83M$36.52M-$26.91M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2025-09-30$68.13M$31.54M$24.66M$92.15M-$59.73M
2024-09-30$44.68M$20.48M$16.97M$56.41M-$36.65M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$100.25M$44.71M$34.79M$127.22M$0.00-$73.20M
2024-12-31$65.12M$29.24M$26.18M$81.14M$0.00-$54.76M
2023-12-31$11.99M$5.69M$17.94M$42.16M(m)-$44.10M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77
SpyGlass Pharma, Inc. (SGP)United States$0.925B
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
IRADIMED CORP (IRMD)United States$1.089B52.92
ARTIVION, INC. (AORT)United States$1.123B-345.09
SI-BONE, Inc. (SIBN)United States$0.830B-49.82
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
MIMEDX GROUP, INC. (MDXG)United States$0.687B89.92
ANGIODYNAMICS INC (ANGO)United States$0.632B-13.02
ORTHOPEDIATRICS CORP (KIDS)United States$0.592B